Clinical Trials at The University of Texas M. D. Anderson Cancer Center
As of August 2026, 68 paid clinical trials are recruiting at The University of Texas M. D. Anderson Cancer Center, located at 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028, phone (713) 794-1464 in Houston, Texas. Active studies at this site cover conditions such as Breast Cancer, Advanced Solid Tumor and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
68 clinical trials at The University of Texas M. D. Anderson Cancer Center
·Clear filters·A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
Decoupling Immunotherapy Toxicity and Cancer Response
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
CARE-BI:a Pilot Study to Improve Patient Comfort and Reduce Psychological Distress During IA Removal
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Interactive Design of Patient-Specific Molds for Tissue Shaping
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Active Living After Cancer: Implementation Within Be Well Acres Homes
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
Common conditions studied in Houston
- Breast Cancer (78 active studies)
- Advanced Solid Tumor (53 active studies)
- Acute Myeloid Leukemia (52 active studies)
- Ovarian Cancer (47 active studies)
- Colorectal Cancer (44 active studies)
- Prostate Cancer (44 active studies)
Leading research sponsors in Houston
- M.D. Anderson Cancer Center
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
- AstraZeneca
- The Methodist Hospital Research Institute
Frequently asked questions
How many paid clinical trials are currently recruiting in Houston?
There are approximately 3,038 recruiting clinical trials in Houston, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Houston pay participants?
Most recruiting trials in Houston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Houston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Houston?
The most common conditions under active study in Houston include Breast Cancer (78), Advanced Solid Tumor (53), Acute Myeloid Leukemia (52), Ovarian Cancer (47), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Houston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Houston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Houston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Houston?
Recruiting research sites in Houston include MD Anderson Cancer Center, M D Anderson Cancer Center, Baylor College of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Houston right now?
The largest active categories in Houston are Cancer & tumors (1,182), Neurology & pain (142), Diabetes & metabolic (101). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of The University of Texas M. D. Anderson Cancer Center?
The University of Texas M. D. Anderson Cancer Center is located at 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028. Use the Google Maps link in the intro above to get directions.
How do I contact The University of Texas M. D. Anderson Cancer Center?
You can reach The University of Texas M. D. Anderson Cancer Center by phone at (713) 794-1464. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.